SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-20-010995
Filing Date
2020-05-15
Accepted
2020-05-15 16:02:28
Documents
64
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20200331_10q.htm 10-Q 804178
2 EXHIBIT 31.1 ex_184666.htm EX-31.1 9489
3 EXHIBIT 32.1 ex_184667.htm EX-32.1 4877
  Complete submission text file 0001437749-20-010995.txt   4940042

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20200331.xml EX-101.INS 879953
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20200331.xsd EX-101.SCH 52586
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20200331_cal.xml EX-101.CAL 36228
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20200331_def.xml EX-101.DEF 438764
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20200331_lab.xml EX-101.LAB 333609
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20200331_pre.xml EX-101.PRE 454453
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 20884860
SIC: 2835 In Vitro & In Vivo Diagnostic Substances